Katja Weisel
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Ludwig H, Terpos E, van de Donk N, Mateos M, Moreau P, Dimopoulos M, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, Gay F, Einsele H, Mina R, Caers J, Driessen C, Musto P, Zweegman S, Engelhardt M, Cook G, Weisel K, Broijl A, Beksac M, Bila J, Schjesvold F, Cavo M, Hájek R, Touzeau C, Boccadoro M, Sonneveld P. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol 2023; 24:e255-e269.
Jun 1, 2023Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Jun 1, 2023Lancet Oncol 2023; 24:e255-e269
Ludwig Heinz, Terpos Evangelos, van de Donk Niels, Mateos Maria-Victoria, Moreau Philippe, Dimopoulos Melitios-Athanasios, Delforge Michel, Rodriguez-Otero Paula, San-Miguel Jesús F, Yong Kwee, Gay Francesca, Einsele Hermann, Mina Roberto, Caers Jo, Driessen Christoph, Musto Pellegrino, Zweegman Sonja, Engelhardt Monika, Cook Gordon, Weisel Katja, Broijl Annemiek, Beksac Meral, Bila Jelena, Schjesvold Fredrik, Cavo Michele, Hájek Roman, Touzeau Cyrille, Boccadoro Mario, Sonneveld Pieter
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos M, Richardson P, Bahlis N, Grosicki S, Cavo M, Beksac M, Legieć W, Liberati A, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach J, Petrucci M, Reece D, White D, Mateos M, Špička I, Lazaroiu M, Berdeja J, Kaufman J, Jou Y, Ganetsky A, Popa McKiver M, Lonial S, Weisel K, Driessen C. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 2022; 9:e403-e414.
May 9, 2022Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
May 9, 2022Lancet Haematol 2022; 9:e403-e414
Dimopoulos Meletios A, Richardson Paul G, Bahlis Nizar, Grosicki Sebastian, Cavo Michele, Beksac Meral, Legieć Wojciech, Liberati Anna Marina, Goldschmidt Hartmut, Belch Andrew, Magen Hila, Larocca Alessandra, Laubach Jacob, Petrucci Maria Teresa, Reece Donna, White Darrell, Mateos Maria-Victoria, Špička Ivan, Lazaroiu Mihaela, Berdeja Jesus G, Kaufman Jonathan L, Jou Ying-Ming, Ganetsky Alex, Popa McKiver Mihaela, Lonial Sagar, Weisel Katja, Driessen Christoph
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Ludwig H, Weisel K, Jackson G, Garderet L, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Schreder M, Abildgaard N, Hájek R, Zojer N, Kastritis E, Broijl A, Schjesvold F, Boccadoro M, Caers J, Delforge M, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, Mateos M, Moreau P, Cavo M, Pawlyn C, Zweegman S, Engelhardt M, Driessen C, Cook G, Dimopoulos M, Gay F, Einsele H, Terpos E. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol 2021; 8:e934-e946.
Oct 28, 2021COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Oct 28, 2021Lancet Haematol 2021; 8:e934-e946
Ludwig Heinz, Weisel Katja, Jackson Graham, Garderet Laurent, van de Donk Niels, Leleu Xavier, Goldschmidt Hartmut, Beksac Meral, Nijhof Inger, Schreder Martin, Abildgaard Niels, Hájek Roman, Zojer Niklas, Kastritis Efstathios, Broijl Annemiek, Schjesvold Fredrik, Boccadoro Mario, Caers Jo, Delforge Michel, Sonneveld Pieter, Facon Thierry, San-Miguel Jesus, Avet-Loiseau Hervé, Mohty Mohamad, Mateos Maria-Victoria, Moreau Philippe, Cavo Michele, Pawlyn Charlotte, Zweegman Sonja, Engelhardt Monika, Driessen Christoph, Cook Gordon, Dimopoulos Melitios A, Gay Francesca, Einsele Hermann, Terpos Evangelos
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Richardson P, Goldschmidt H, Harousseau J, Dytfeld D, Mellqvist U, Chng W, Hou J, Bergsagel P, Riva E, Leleu X, Bladé J, Driessen C, Quach H, Ocio E, Vesole D, Waage A, Laubach J, Munshi N, Gay F, Dimopoulos M, Rajkumar S, Mateos M, Cook G, Nahi H, Harrison S, Sezer O, Holstein S, Zweegman S, Usmani S, Boccadoro M, Hari P, Kaiser M, Costa L, Beksac M, Maiolino A, Leal da Costa F, Sidana S, Jurczyszyn A, Facon T, Durie B, Yong K, Martin T, Schjesvold F, Terpos E, Mikhael J, Ludwig H, Bahlis N, Zamagni E, Davies F, San Miguel J, Kumar S, Raje N, van de Donk N, Lonial S, Berdeja J, Hungria V, Baz R, Weisel K, Vangsted A, Fonseca R, Engelhardt M, Sonneveld P, Einsele H, João C, Anderson K, Hájek R, Lentzsch S, Kristinsson S, Cavo M, Moreau P. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol 2021; 22:e105-e118.
Jan 1, 2021Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Jan 1, 2021Lancet Oncol 2021; 22:e105-e118
Richardson Paul G, Goldschmidt Hartmut, Harousseau Jean-Luc, Dytfeld Dominik, Mellqvist Ulf-Henrik, Chng Wee Joo, Hou Jian, Bergsagel Peter Leif, Riva Eloisa, Leleu Xavier, Bladé Joan, Driessen Christoph, Quach Hang, Ocio Enrique M, Vesole David H, Waage Anders, Laubach Jacob, Munshi Nikhil C, Gay Francesca, Dimopoulos Meletios A, Rajkumar S Vincent, Mateos Maria-Victoria, Cook Gordon, Nahi Hareth, Harrison Simon, Sezer Orhan, Holstein Sarah, Zweegman Sonja, Usmani Saad Z, Boccadoro Mario, Hari Parameswaran, Kaiser Martin, Costa Luciano J, Beksac Meral, Maiolino Angelo, Leal da Costa Fernando, Sidana Surbhi, Jurczyszyn Artur, Facon Thierry, Durie Brian G M, Yong Kwee, Martin Thomas, Schjesvold Fredrik, Terpos Evangelos, Mikhael Joseph, Ludwig Heinz, Bahlis Nizar, Zamagni Elena, Davies Faith, San Miguel Jesús, Kumar Shaji K, Raje Noopur, van de Donk Niels, Lonial Sagar, Berdeja Jesus G, Hungria Vania, Baz Rachid, Weisel Katja, Vangsted Annette, Fonseca Rafael, Engelhardt Monika, Sonneveld Pieter, Einsele Hermann, João Cristina, Anderson Kenneth C, Hájek Roman, Lentzsch Suzanne, Kristinsson Sigurdur Y, Cavo Michele, Moreau Philippe
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Ludwig H, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, Engelhardt M, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Abildgaard N, Bringhen S, Mateos M, Mohty M, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, Zweegman S, Facon T, Driessen C, Hájek R, Dimopoulos M, Gay F, Avet-Loiseau H, Terpos E, Zojer N, Sonneveld P. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 2020; 35:31-44.
Aug 19, 2020Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Aug 19, 2020Leukemia 2020; 35:31-44
Ludwig Heinz, Einsele Hermann, Delforge Michel, Caers Jo, Weisel Katja, Jackson Graham, Garderet Laurent, Engelhardt Monika, van de Donk Niels, Leleu Xavier, Goldschmidt Hartmut, Beksac Meral, Nijhof Inger, Abildgaard Niels, Bringhen Sara, Mateos Maria-Victoria, Mohty Mohamad, Boccadoro Mario, Moreau Philippe, San-Miguel Jesus, Cavo Michele, Pawlyn Charlotte, Zweegman Sonja, Facon Thierry, Driessen Christoph, Hájek Roman, Dimopoulos Melitios A, Gay Francesca, Avet-Loiseau Hervé, Terpos Evangelos, Zojer Niklas, Sonneveld Pieter
Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma
Bilich T, Stevanovic S, Rammensee H, Neidert M, Schuhmacher J, Lübke M, Marcu A, Besemer B, Weisel K, Salih H, Roerden M, Walz S, Bauer J, Nelde A, Walz J. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma. Blood Cancer J 2020; 10:24.
Feb 28, 2020Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma
Feb 28, 2020Blood Cancer J 2020; 10:24
Bilich Tatjana, Stevanovic Stefan, Rammensee Hans-Georg, Neidert Marian Christoph, Schuhmacher Juliane, Lübke Maren, Marcu Ana, Besemer Britta, Weisel Katja, Salih Helmut R, Roerden Malte, Walz Simon, Bauer Jens, Nelde Annika, Walz Juliane S
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
Ludwig H, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk N, Waage A, Beksac M, Mellqvist U, Engelhardt M, Caers J, Driessen C, Bladé J, Mateos M, Garderet L, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hájek R, Mohty M, Cavo M, Dimopoulos M, San-Miguel J, Terpos E, Zweegman S, Sonneveld P. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 2018
May 2, 2018Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
May 2, 2018Leukemia 2018
Ludwig Heinz, Cook Gordon, Leleu Xavier, Goldschmidt Hartmut, Jackson Graham, Kaiser Martin, Weisel Katja, van de Donk Niels W C J, Waage Anders, Beksac Meral, Mellqvist Ulf H, Engelhardt Monika, Caers Jo, Driessen Christoph, Bladé Joan, Mateos Maria-Victoria, Garderet Laurent, Delforge Michel, Facon Thierry, Einsele Hermann, Gay Francesca, Moreau Philippe, Avet-Loiseau Hervé, Boccadoro Mario, Hájek Roman, Mohty Mohamad, Cavo Michele, Dimopoulos Meletios A, San-Miguel Jesús F, Terpos Evangelos, Zweegman Sonja, Sonneveld Pieter
A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens
Backert L, Stevanovic S, Rammensee H, Weisel K, Kohlbacher O, Salih H, Kanz L, Niederwieser D, Vucinic V, Brümmendorf T, Schemionek M, Neidert M, Berlin C, Schuster H, Walz S, Kowalewski D, Walz J. A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens. Oncotarget 2017; 8:43915-43924.
Jul 4, 2017A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens
Jul 4, 2017Oncotarget 2017; 8:43915-43924
Backert Linus, Stevanovic Stefan, Rammensee Hans-Georg, Weisel Katja, Kohlbacher Oliver, Salih Helmut Rainer, Kanz Lothar, Niederwieser Dietger, Vucinic Vladan, Brümmendorf Tim H, Schemionek Mirle, Neidert Marian Christoph, Berlin Claudia, Schuster Heiko, Walz Simon, Kowalewski Daniel Johannes, Walz Juliane Sarah
Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury.
Heyne N, Denecke B, Guthoff M, Oehrlein K, Kanz L, Häring H, Weisel K. Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. Ann Hematol 2011; 91:729-735.
Dec 15, 2011Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury.
Dec 15, 2011Ann Hematol 2011; 91:729-735
Heyne Nils, Denecke Barbara, Guthoff Martina, Oehrlein Katharina, Kanz Lothar, Häring Hans-Ulrich, Weisel Katja